title: New therapies for advanced glycation end product nephrotoxicity: current challenges.
abstract: BACKGROUND
  The role of advanced glycation end products (AGEs) in diabetic nephropathy has been developed during several years of research and increasingly complex AGE biochemistry. However, the structural diversity of AGE chemistry has created new challenges in the search for AGE-based inhibition therapies.
  
  
  RESULTS
  The challenges include the need to standardize measurements of serum and tissue AGE levels, identifying nephrotoxic AGE compounds, understanding the cell biological state of AGEs in the diabetic kidney, determining the mechanism of action of selective inhibition of the glycation cascade, and forming complementary therapies.
  
  
  CONCLUSIONS
  Current challenges in the development of new therapies for AGE nephrotoxicity are reviewed.
authors.affiliation: Joslin Diabetes Center and Harvard Medical School, Boston, MA, USA. mark.williams@joslin.harvard.edu
authors.forename: Mark E
authors.initials: ME
authors.lastname: Williams
mesh_terms: D000818:Animals; D003928:Diabetic Nephropathies / Q000139:chemically induced* / Q000188:drug therapy*; D017127:Glycation End Products, Advanced / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D006801:Humans
chemical_list: D017127:Glycation End Products, Advanced